文献速递呼吸道感染

COVID-19相关肺曲霉病的危险因素:系统综述与荟萃分析

Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis.
PubMed 文献 · Lancet Respir Med · 2024-01-04

识别出8项CAPA危险因素,包括慢性肝病、血液恶性肿瘤、慢阻肺、脑血管病、有创机械通气、肾脏替代治疗、IL-6抑制剂及糖皮质激素治疗。CAPA患者年龄更大、机械通气时间更长,且全因死亡率更高。

要点

  • 慢性肝病、血液恶性肿瘤、慢阻肺及脑血管病增加CAPA风险。
  • 有创机械通气、肾脏替代治疗、IL-6抑制剂及糖皮质激素治疗与CAPA相关。

核心结论

  • 识别出的CAPA危险因素或可指导重症COVID-19患者的目标性抗真菌预防。

研究设计与样本

  • 系统综述与荟萃分析,检索5个医学数据库,纳入27项病例对照及队列研究,共6848例COVID-19成人患者。

临床怎么用

  • 对具备慢性肝病、血液恶性肿瘤、慢阻肺、脑血管病及接受有创机械通气、肾脏替代治疗、IL-6抑制剂或糖皮质激素治疗的重症COVID-19患者,应警惕CAPA风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19-associated pulmonary aspergillosis (CAPA) has been reported to be an emerging and potentially fatal complication of severe COVID-19. However, risk factors for CAPA have not been systematically addressed to date. METHODS: In this systematic review and meta-analysis to identify factors associated with CAPA, we comprehensively searched five medical databases: Ovid MEDLINE; Ovid Embase; the Cochrane Database of Systematic Reviews; the Cochrane Central Register of Controlled Trials; and the WHO COVID-19 Database. All case-control and cohort studies in adults (aged >18 years) that described at least six cases of CAPA and evaluated any risk factors for CAPA, published from Dec 1, 2019, to July 27, 2023, were screened and assessed for inclusion. Only studies with a control population of COVID-19-positive individuals without aspergillosis were included. Two reviewers independently screened search results and extracted outcome data as summary estimates from eligible studies. The primary outcome was to identify the factors associated with CAPA. Meta-analysis was done with random-effects models, with use of the Mantel-Haenszel method to assess dichotomous outcomes as potential risk factors, or the inverse variance method to assess continuous variables for potential association with CAPA. Publication bias was assessed with funnel plots for factors associated with CAPA. The study is registered with PROSPERO, CRD42022334405. FINDINGS: Of 3561 records identified, 27 articles were included in the meta-analysis. 6848 patients with COVID-19 were included, of whom 1324 (19·3%) were diagnosed with CAPA. Diagnosis rates of CAPA ranged from 2·5% (14 of 566 patients) to 47·2% (58 of 123). We identified eight risk factors for CAPA. These factors included pre-existing comorbidities of chronic liver disease (odds ratio [OR] 2·70 [95% CI 1·21-6·04], p=0·02; I2=53%), haematological malignancies (OR 2·47 [1·27-4·83], p=0·008; I2=50%), chronic obstructive pulmonary disease (OR 2·00 [1·42-2·83], p<0·0001; I2=26%), and cerebrovascular disease (OR 1·31 [1·01-1·71], p=0·05; I2=46%). Use of invasive mechanical ventilation (OR 2·83; 95% CI 1·88-4·24; p<0·0001; I2=69%), use of renal replacement therapy (OR 2·26 [1·76-2·90], p<0·0001; I2=14%), treatment of COVID-19 with interleukin-6 inhibitors (OR 2·88 [1·52-5·43], p=0·001; I2=89%), and treatment of COVID-19 with corticosteroids (OR 1·88 [1·28-2·77], p=0·001; I2=66%) were also associated with CAPA. Patients with CAPA were typically older than those without CAPA (mean age 66·6 years [SD 3·6] vs 63·5 years [5·3]; mean difference 2·90 [1·48-4·33], p<0·0001; I2=86%). The duration of mechanical ventilation in patients with CAPA was longer than in those without CAPA (n=7 studies; mean duration 19·3 days [8·9] vs 13·5 days [6·8]; mean difference 5·53 days [1·30-9·77], p=0·01; I2=88%). In post-hoc analysis, patients with CAPA had higher all-cause mortality than those without CAPA (n=20 studies; OR 2·65 [2·04-3·45], p<0·0001; I2=51%). INTERPRETATION: The identified risk factors for CAPA could eventually be addressed with targeted antifungal prophylaxis in patients with severe COVID-19. FUNDING: None.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Gioia F, Walti LN, Orchanian-Cheff A, et al. Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. Lancet Respir Med. 2024. PMID: 38185135. doi:10.1016/S2213-2600(23)00408-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。